https://www.youtube.com/watch?v=cdkl4IyPweQ
Welcome to FOXO Technologies,
the Longevity Company
Modernizing the longevity insurance industry with molecular biotechnology.
Why We Do It
We believe that changes to the human epigenome are a fundamental mechanism of aging and disease.
As we reimagine the future of longevity insurance underwriting and support the growth of global longevity markets with a next-generation underwriting protocol, we seek to discover and understand the role epigenetic biomarkers play in individual health, wellness, and aging in order to empower people to improve the length and quality of their lives, and make more informed choices that benefit their health.
While a person’s underlying genetic code is stable throughout life, their health, wellness and aging leave discernible marks on the genome that modify how genes are expressed. The epigenome is the combination of all such natural modifications; while epigenetic modifications can register within seconds to minutes, they can imprint signatures on the epigenome for decades, leaving a unique biography of an individual’s health and wellness history.
Smoking tobacco is a leading cause of cancer
Stress promotes Cardiovascular Disease
Obesity can cause genes to express as Diabetes
Diet & Exercise can increase/decrease Disease States
How We Do It
To identify epigenetic biomarkers along the epigenome, we apply advanced supervised machine learning and artificial intelligence technologies to create predictive models that correlate epigenetic profiles with states of health, wellness, disease, and aging. Our high throughput, CLIA-certified laboratories also support human and mouse epigenetic methylation testing for the scientific research community.
Who We Serve
Research Community
As a molecular biotechnology company, we are developing innovative new products and epigenetic testing services that provide cost-effective solutions for the scientific research community.
Longevity Industry
We are using epigenetics to reimagine the future of life insurance with a next-generation underwriting protocol and consumer engagement platform focused on improving human health and lifespan.
Our Ecosystem
We collaborate with some of the nation’s leading bioscience and biotechnology companies, academic institutions, and science education organizations to develop cutting-edge epigenetic technology.
Follow our CEO, Jon Sabes’ approach to longevity and legacy.
Featured Articles
FOXO in On the Risk
Read about the current state of insurance underwriting and how we are using molecular biotechnology to reimagine it in “The Need to Evolve Preferred Underwriting” by FOXO Chief Underwriter, Bill Moore.
FOXO in Society of Actuaries
Understand how the science of epigenetics is positioned to impact life insurance, and learn how the utilization of epigenetic biomarkers for underwriting could transform the longevity insurance industry.
Follow along on our journey to transform the global longevity insurance industry.
You may unsubscribe whenever you wish.
Epigenetics & Longevity in the Media
Epigenetic Aging: How old is your DNA?
Dr. Steve Horvath, a professor of genetics and biostatistics at UCLA, has found a way to measure biological aging – a type of “clock” – based on the methylation pattern of an organism’s genome.
David Sinclair & Joe Rogan
Our journey started with Dr. Steve Horvath’s research into aging. Listen to Dr. David Sinclair explain who Dr. Horvath is and why our technology is fundamental to understanding aging.
The Power of the
Epigenetic Clock
In this TEDxBerkeley Talk, Dr. Steve Horvath of the University of California, Los Angeles explores how epigenetic clocks are currently being used to discover anti-aging treatments.